Nicola Normanno
#139,133
Most Influential Person Now
Researcher
Nicola Normanno's AcademicInfluence.com Rankings
Nicola Normannocomputer-science Degrees
Computer Science
#6569
World Rank
#6926
Historical Rank
Machine Learning
#2179
World Rank
#2207
Historical Rank
Artificial Intelligence
#2445
World Rank
#2486
Historical Rank
Database
#3653
World Rank
#3804
Historical Rank
Download Badge
Computer Science
Nicola Normanno's Degrees
- PhD Computer Science University of Milan
- Masters Computer Science University of Milan
- Bachelors Computer Science University of Milan
Similar Degrees You Can Earn
Why Is Nicola Normanno Influential?
(Suggest an Edit or Addition)Nicola Normanno's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Epidermal growth factor-related peptides and their receptors in human malignancies. (1995) (2800)
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- Epidermal growth factor receptor (EGFR) signaling in cancer. (2006) (1750)
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches (2012) (625)
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. (2011) (533)
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) (432)
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC (2009) (403)
- Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. (2003) (365)
- The role of the EGFR signaling in tumor microenvironment (2008) (336)
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. (2002) (294)
- Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. (2005) (289)
- The ErbB receptors and their ligands in cancer: an overview. (2005) (279)
- Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. (2006) (263)
- Implementing TMB measurement in clinical practice: considerations on assay requirements (2019) (215)
- Leptin signaling in breast cancer: An overview (2008) (215)
- The role of EGF-related peptides in tumor growth. (2001) (196)
- Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (2009) (180)
- Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line (2011) (169)
- Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis (2005) (169)
- Guidance for laboratories performing molecular pathology for cancer patients (2014) (165)
- Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. (2003) (153)
- ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study (2016) (150)
- Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells (2002) (145)
- EGFR Mutation Testing Practices within the Asia Pacific Region (2015) (143)
- Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV‐Cripto‐1 transgenic mice (2004) (141)
- The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib (2006) (141)
- VEGF as a potential target in lung cancer (2017) (141)
- Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. (1992) (138)
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action? (2003) (134)
- Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level (2004) (131)
- The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. (2000) (127)
- Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. (2015) (125)
- Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. (1994) (122)
- Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells. (1994) (109)
- TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction (2013) (109)
- EGFR-targeted therapy. (2011) (108)
- Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel (2013) (105)
- Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer (2016) (105)
- Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells* (1997) (105)
- A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. (2003) (102)
- The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. (2018) (99)
- Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. (2005) (97)
- EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. (2017) (97)
- Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. (1994) (95)
- The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. (2018) (94)
- Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. (2014) (92)
- Mesenchymal stem cell‐derived interleukin‐6 and vascular endothelial growth factor promote breast cancer cell migration (2012) (89)
- Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells (2011) (88)
- Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer (2006) (86)
- EGFR mutations in lung cancer: from tissue testing to liquid biopsy. (2015) (83)
- RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial (2018) (83)
- Role of human cripto-1 in tumor angiogenesis. (2005) (83)
- Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. (2020) (82)
- Target-based therapies in breast cancer: current status and future perspectives. (2009) (81)
- Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma (2016) (81)
- Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. (2012) (79)
- Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. (1995) (78)
- Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL (2016) (76)
- Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor γ Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome (2010) (75)
- Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. (2002) (75)
- Regulation by Estrogen through the 5′-Flanking Region of the Transforming Growth Factor α Gene (1991) (75)
- Guideline on the requirements of external quality assessment programs in molecular pathology (2012) (74)
- Additive effects of c‐erbB‐2, c‐Ha‐ras, and transforming growth factor‐α genes on in vitro transformation of human mammary epithelial cells (1992) (73)
- Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. (2000) (73)
- Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. (2016) (72)
- Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma (2005) (71)
- Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts (2000) (71)
- Cripto-1: an oncofetal gene with many faces. (2005) (70)
- Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas (1995) (66)
- Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities (2013) (64)
- The role of amphiregulin in breast cancer (2004) (64)
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2022) (63)
- Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer (2017) (63)
- Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. (1994) (63)
- Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. (2013) (63)
- Expression of amphiregulin, cripto-1, and heregulin-alpha in human breast-cancer cells. (1993) (62)
- Angiogenesis Inhibitors in NSCLC (2017) (61)
- Epidermal growth factor-related peptides in the pathogenesis of human breast cancer (2004) (61)
- Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. (1996) (60)
- Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases (2006) (60)
- Cripto‐1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF‐7 breast cancer cells (2004) (60)
- Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. (2018) (58)
- Delivering precision oncology to patients with cancer (2022) (57)
- Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. (2014) (55)
- FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention (2020) (55)
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022) (55)
- Expression of transforming growth factor α antisense mRNA inhibits the estrogen‐induced production of TGFα and estrogen‐induced proliferation of estrogen‐responsive human breast cancer cells (1993) (52)
- Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. (2010) (52)
- The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies (2013) (52)
- Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia (2011) (52)
- Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology (2013) (52)
- ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. (2021) (51)
- Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? (2006) (51)
- Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. (1991) (49)
- EGF-Related Peptides in the Pathophysiology of the Mammary Gland (1997) (49)
- Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium (2015) (48)
- Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors (2005) (48)
- Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. (2021) (48)
- Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling (2008) (48)
- The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies☆ (2021) (47)
- Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. (2021) (47)
- Gefitinib in Non Small Cell Lung Cancer (2011) (46)
- Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib (2014) (46)
- Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. (2019) (46)
- Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells (2016) (45)
- Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. (2010) (45)
- EGF‐related peptides are involved in the proliferation and survival of MDA‐MB‐468 human breast carcinoma cells (1999) (45)
- External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. (2015) (44)
- Regulation of human cripto‐1 gene expression by TGF‐β1 and BMP‐4 in embryonal and colon cancer cells (2008) (44)
- Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. (2019) (43)
- Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity (2016) (43)
- Practical considerations in screening for genetic alterations in cholangiocarcinoma. (2021) (42)
- Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells (2010) (42)
- Expression and functional role of CRIPTO-1 in cutaneous melanoma (2011) (41)
- Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing (2014) (41)
- 96ODETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDY (2015) (41)
- The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients (2019) (40)
- Development of leiomyosarcoma of the uterus in MMTV‐CR‐1 transgenic mice (2007) (40)
- Recommendations for mutational analysis of EGFR in lung carcinoma. (2010) (39)
- Anti‐sense oligonucleotides directed against EGF‐related growth factors enhance anti‐proliferative effect of conventional anti‐tumor drugs in human colon‐cancer cells (1997) (39)
- Recommendations for mutational analysis of EGFR in lung carcinoma. (2010) (39)
- Cetuximab in non-small-cell lung cancer (2012) (39)
- Quercetin‐3‐methyl ether inhibits lapatinib‐sensitive and ‐resistant breast cancer cell growth by inducing G2/M arrest and apoptosis (2013) (38)
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM) (2017) (38)
- EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer (2019) (38)
- Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo (2005) (38)
- Immunotherapy in Small Cell Lung Cancer (2020) (38)
- Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology (2013) (36)
- Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer (2013) (36)
- Gefitinib inhibits the cross‐talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity (2013) (35)
- Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma (2015) (35)
- EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. (2000) (35)
- Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. (2010) (35)
- BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2016) (35)
- Triple negative breast cancer: from molecular portrait to therapeutic intervention. (2010) (34)
- A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. (2009) (34)
- Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. (2017) (34)
- Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. (2019) (34)
- KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment (2011) (34)
- Aging and the hemopoietic system. (2003) (34)
- Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. (2014) (34)
- Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. (2018) (33)
- HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. (2011) (33)
- New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. (2005) (33)
- Infection with a transforming growth factor α anti‐sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line (1993) (33)
- Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer (2019) (33)
- Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion (2019) (33)
- EGFR and MEK Blockade in Triple Negative Breast Cancer Cells (2015) (32)
- A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. (2011) (32)
- Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? (2013) (32)
- International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA (2018) (31)
- Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. (2016) (30)
- CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. (2004) (30)
- Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. (1998) (30)
- Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. (2016) (30)
- Amphiregulin anti‐sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line (1995) (29)
- Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer (2005) (29)
- The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies. (2021) (29)
- Vandetanib: An overview of its clinical development in NSCLC and other tumors. (2010) (29)
- Role of the cripto (EGF-CFC) family in embryogenesis and cancer. (2004) (29)
- Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial (2006) (28)
- Methodology of clinical trials with new molecular-targeted agents: where do we stand? (2006) (27)
- The significance of a Cripto-1-positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics (2013) (26)
- Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment (2017) (26)
- Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case (2018) (26)
- Targeting the EGFR T790M mutation in non-small-cell lung cancer (2017) (26)
- Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation (2019) (26)
- ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. (2022) (26)
- RAS testing in metastatic colorectal cancer: advances in Europe (2015) (26)
- Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. (2014) (26)
- IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing (2019) (26)
- Enhanced expression of heregulin in c‐erb B‐2 and c‐Ha‐ras transformed mouse and human mammary epithelial cells (1996) (25)
- Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. (1999) (25)
- Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents (2019) (25)
- Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. (2015) (25)
- Regulation of Cripto-1 signaling and biological activity by caveolin-1 in mammary epithelial cells. (2008) (24)
- FGFR-targeted therapeutics for the treatment of breast cancer (2017) (24)
- Regulation by estrogen through the 5'-flanking region of the transforming growth factor alpha gene. (1991) (24)
- Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. (1991) (24)
- Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. (2011) (23)
- Angiogenesis Inhibitors in Small Cell Lung Cancer (2021) (23)
- European consensus conference for external quality assessment in molecular pathology. (2013) (23)
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. (2005) (23)
- Right-sided rhabdoid colorectal tumors might be related to the Serrated Pathway (2013) (23)
- Detection and localization of Cripto‐1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin–cripto‐1 fusion protein † (2002) (22)
- Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. (2016) (22)
- Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer (2013) (21)
- Immunohistochemical detection of cripto-1, amphiregulin and transforming growth-factor-alpha in human gastric carcinomas and intestinal metaplasias. (1994) (21)
- Prognostic Applications of Gene Expression Signatures in Breast Cancer (2010) (21)
- Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families. (1999) (21)
- RET Inhibitors in Non-Small-Cell Lung Cancer (2021) (20)
- Circulating tumour cells (2011) (20)
- ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme (2014) (20)
- Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis (2020) (20)
- Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study. (2020) (20)
- Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells (2017) (20)
- RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells (2018) (20)
- Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment? (2013) (20)
- Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management (2020) (20)
- Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls (2020) (19)
- The prognostic role of circulating tumor cells in lung cancer (2016) (19)
- AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib (2007) (19)
- Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC) (2018) (19)
- Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study (2018) (19)
- Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey (2017) (19)
- AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. (2020) (18)
- Neuronal guidance protein Netrin-1 induces differentiation in human embryonal carcinoma cells. (2009) (18)
- RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells (2014) (18)
- BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features (2016) (18)
- Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series. (2019) (18)
- 397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study (2020) (17)
- The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. (2019) (17)
- The role of circulating free DNA in the management of NSCLC (2018) (17)
- Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. (2021) (17)
- The International Collaboration for Cancer Classification and Research (2020) (17)
- Bevacizumab in non small cell lung cancer: development, current status and issues. (2012) (17)
- Use of biological prostheses in transplant patients with incisional hernias. Preliminary experience. (2013) (16)
- Structure-fluctuation-function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis. (2015) (16)
- Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer (2018) (16)
- Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. (2017) (15)
- Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. (2012) (15)
- Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. (2008) (15)
- Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study (2019) (15)
- 35O_PRINVESTIGATING THE UTILITY OF CIRCULATING-FREE TUMOUR-DERIVED DNA (CTDNA) IN PLASMA FOR THE DETECTION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION STATUS IN EUROPEAN AND JAPANESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC): ASSESS STUDY (2015) (15)
- Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? (2004) (14)
- Pharmacokinetic evaluation of zoledronic acid (2011) (14)
- The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences (2015) (14)
- Small Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: An Overview (2004) (13)
- Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL (2020) (13)
- KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting (2014) (13)
- New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development (2010) (13)
- Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives (2013) (13)
- Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. (2013) (13)
- Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models (2015) (13)
- Vandetanib as a potential treatment for breast cancer (2014) (12)
- Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. (2019) (12)
- The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies (2022) (11)
- Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? (2005) (11)
- Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials (2005) (11)
- Apolipoprotein A-I reverse transcriptase-polymerase chain reaction analysis for detection of hematogenous colon cancer dissemination. (1998) (11)
- Molecular Tests and Target Therapies in Oncology: recommendations from the Italian workshop. (2021) (10)
- LBA-09Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab (2015) (10)
- SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system (2021) (10)
- Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis (2021) (10)
- Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination? (2005) (10)
- Pharmacokinetic evaluation of capecitabine in breast cancer (2013) (10)
- Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients (2020) (10)
- Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies (2022) (9)
- Osteoblastic metastases in non-small cell lung cancer and its possible significance. (2008) (9)
- Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications (2020) (9)
- Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib. (2012) (9)
- In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies (2022) (9)
- Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial (2016) (9)
- Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol (2019) (9)
- Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives (2022) (9)
- Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer (2015) (9)
- D02*Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial (2016) (9)
- The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells (2019) (8)
- Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. (2004) (8)
- Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment. (2010) (8)
- Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro? (2004) (8)
- External quality assessment for EGFR mutations in Italy: improvements in performances over the time (2017) (8)
- Expression of transforming growth factor alpha antisense mRNA inhibits the estrogen-induced production of TGF alpha and estrogen-induced proliferation of estrogen-responsive human breast cancer cells. (1993) (8)
- Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018) (2020) (8)
- Genomics driven-oncology: challenges and perspectives (2015) (7)
- Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib (2019) (7)
- Treatment of small cell lung cancer. (2014) (7)
- Abstract 36: The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers. (2013) (7)
- Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. (2012) (7)
- Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence (2011) (7)
- Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients. (2019) (7)
- Surgery in Small-Cell Lung Cancer (2021) (7)
- Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy. (2016) (7)
- Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association (2020) (7)
- Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT) (2020) (7)
- 36 DETECTION OF KRAS MUTATIONS IN COLORECTAL CARCINOMA PATIENTS WITH AN INTEGRATED PCR/SEQUENCING AND REAL TIME PCR APPROACH (2010) (7)
- 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial (2021) (7)
- Role of molecular genetics in the clinical management of cholangiocarcinoma (2022) (7)
- Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma (2015) (7)
- Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial. (2022) (7)
- Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity. (2021) (6)
- CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients (2022) (6)
- Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. (2012) (6)
- Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial (2022) (6)
- Breast cancer in the post-genomic era / (2009) (6)
- Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016 (2016) (6)
- Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management (2022) (6)
- Erlotinib in pancreatic cancer: are tumor cells the (only) target? (2007) (6)
- Prognostic factor for non-small cell lung cancer with bone metastases at the time of diagnosis. (2012) (5)
- Mechanisms of action of EGFR inhibitors (2012) (5)
- COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC) (2021) (5)
- Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site (2016) (5)
- Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience: 580_PR (2016) (5)
- Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development (2021) (5)
- Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell’Italia Meridionale (GOIM). (2013) (5)
- The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. (2021) (5)
- Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. (2010) (5)
- Access and quality of biomarker testing for precision oncology in Europe. (2022) (5)
- The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic (2020) (4)
- Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel (2014) (4)
- Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) (2022) (4)
- Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. (2018) (4)
- Modulation of epidermal growth factor receptor-positive circulating tumor cells by chemotherapy in non-small-cell lung cancer patients. (2005) (4)
- Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy (2021) (4)
- Methodological issues of clinical research with EGFR inhibitors (2007) (4)
- Challenges in bioinformatics approaches to tumor mutation burden analysis (2021) (3)
- Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma (2020) (3)
- Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment (2022) (3)
- Lurbinectedin for small cell lung cancer (2021) (3)
- Promising Role of Circulating Tumor Cells in the Management of SCLC (2021) (3)
- Abstract 565: Effects of zoledronic acid on the interaction between mesenchymal stem cells and breast cancer cells (2010) (3)
- BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories (2019) (3)
- Osteoblastosis and activating epidermal growth factor receptor mutations: a relationship? (2010) (3)
- Pembrolizumab in lung cancer: current evidence and future perspectives. (2019) (3)
- New molecular targets for anticancer therapy (1998) (3)
- DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancer. (1995) (3)
- EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer (2021) (3)
- The EGF receptor system as a target for therapy (2008) (3)
- Cells Signaling Pathways in Mammary Epithelial ALK 4-Dependent and-Independent Cripto-1 Activates Nodal-and (2002) (3)
- Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy) (2022) (3)
- Optimizing response to gefitinib in the treatment of non-small-cell lung cancer (2011) (3)
- Tumour mutation burden and microsatellite instability in colorectal cancer (2019) (3)
- 1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM) (2020) (2)
- Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon (2019) (2)
- Faculty Opinions recommendation of Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. (2016) (2)
- External Quality Assessment schemes for biomarker testing in oncology: comparison of performance between formalin-fixed, paraffin-embedded-tissue and cell-free tumor DNA in plasma. (2020) (2)
- Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups (2022) (2)
- Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path) (2021) (2)
- Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’ (2012) (2)
- Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies (2022) (2)
- Effects of gefitinib (G) on bone metatases (BMs) in non-small cell lung cancer patients. (2006) (2)
- A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology. (2007) (2)
- Current status of screening for colorectal cancer (2013) (2)
- Advances in Brief A Nodal-and ALK 4-independent Signaling Pathway Activated by Cripto-1 through Glypican-1 and cSrc 1 (2003) (2)
- Inter-Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma (2016) (2)
- Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC. (2022) (2)
- Mini Review (2004) (2)
- AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). (2018) (2)
- LBA22 Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study (2022) (2)
- Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice (2022) (2)
- cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation? (2020) (1)
- Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis (2022) (1)
- KRAS aKtive, an Italian network for assessment of KRAS mutations in colorectal cancer patients: Results on 7,432 cases. (2012) (1)
- Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis: 59PD (2016) (1)
- In reply [14] (2005) (1)
- Epidermal growth factor-related growth factors in human colorectal cancer (1995) (1)
- Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy) (2022) (1)
- New molecular targets for anticancer therapy. The First International Conference on New Molecular Targets for Anticancer Therapy. Naples, Italy. June 22-23 1998. (1998) (1)
- Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. (2012) (1)
- External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme (2022) (1)
- Expression and prognostic significance of the EGFR in solid tumors (2008) (1)
- Abstract 3975: Tumor mutation burden and microsatellite instability in colorectal cancer (2019) (1)
- BRAF Inhibitors in Non-Small Cell Lung Cancer (2022) (1)
- Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis: results from the Onconetwork Immuno-Oncology Consortium. (2021) (1)
- Letter to the Editor: Reply to Kobunai et al. (2011) (1)
- KRAS mutations in colorectal cancer patients in Italy: Results from the KRAS aKtive program. (2011) (1)
- Abstract 3581: Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib (2011) (1)
- Molecular biology of renal-cell carcinoma (2008) (1)
- Zoledronic acid in early-stage breast cancer. (2011) (1)
- A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine (2021) (1)
- Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. (2023) (1)
- Abstract 2619: Genetic landscape of KRAS-NRAS-BRAF-PIK3CA wild type metastatic colorectal cancer patients enrolled in the CAPRI clinical trial (2018) (1)
- Prioritization of driver genes in cancer-associated copy number alterations identifies B4GALT5 as a glycooncogene (2022) (1)
- O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials (2022) (1)
- EP1120 Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: outcomes from an Institutional series (2019) (1)
- Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy (2022) (1)
- EGFR FASTnet: The Italian network for epidermal growth factor receptors (EGFR) mutation analysis in non-small cell lung cancer (NSCLC). (2011) (1)
- Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets? (2021) (1)
- KRAS in NSCLC: State of the Art and Future Perspectives (2022) (1)
- NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients. (2020) (1)
- The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer (2020) (1)
- 1505MO Improving cancer care through broader access to quality biomarker testing: An IQN Path, ECPC and EFPIA initiative (2021) (1)
- Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the ERMES clinical trial. (2018) (1)
- P3.02b-043 Inter-Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma: Topic: EGFR Biomarkers (2017) (1)
- Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity (2016) (1)
- Results of a Pilot External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non-Small Cell Lung Cancer Managed by EMQN, ESMO, ESP, and ETOP (2011) (1)
- Oncogenes, growth factors, and growth inhibitors in breast cancer (1995) (1)
- Faculty Opinions recommendation of Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. (2012) (1)
- Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC). (2017) (1)
- 24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome (2021) (1)
- Results of a worldwide external quality assessment of cfDNA testing in lung Cancer (2022) (1)
- The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells (2022) (1)
- Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. (2017) (1)
- Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center (2022) (1)
- Zoledronic acid affects the expression of VEGF in breast cancer cells and in bone marrow stromal cells through direct and indirect mechanisms (2008) (1)
- Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics (2022) (1)
- Gene methylation in liquid biopsy and risk of recurrence in lung cancer. (2018) (1)
- [Precision medicine from experimental to clinical applications in oncology]. (2015) (1)
- AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) (2019) (1)
- Plasma ctDNA for the detection of EGFR mutation status in advanced nsclc (aNSCLC) as per local diagnostic practices: Japanese subset data from assess. (2016) (1)
- S04External Quality Assessment Schemes in the management of solid tumors: the Italian perspective (2016) (0)
- Endocrine effects of aromatase inhibitors as adjuvant treatment in postmenopausal breast cancer patients (2011) (0)
- Genomics driven-oncology: challenges and perspectives (2015) (0)
- Faculty Opinions recommendation of Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. (2007) (0)
- Faculty Opinions recommendation of Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. (2014) (0)
- Cetuximab in first line treatment of metastatic colorectal cancer (2012) (0)
- Gefitinib reduces the production of osteoclast differentiation factors in human bone marrow stromal cells: Implications for treatment of bone metastasis (2005) (0)
- 23 ZOLEDRONIC ACID BLOCKS THE INTERACTION BETWEEN MESENCHYMAL STEM CELLS AND BREAST CANCER CELLS (2010) (0)
- Correction to: External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme (2022) (0)
- Liquid biopsies, are we ready for prime time? (2023) (0)
- Epidermal Growth Factor Receptor Mutations in Italian Non-Small-Cell Lung Cancer Patients Enrolled in the EGFR Fastnet Program (2012) (0)
- International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA (2018) (0)
- Findings from the Global External Quality Assessment of Lung Cancer Liquid Biopsy Testing (2019) (0)
- Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer (2020) (0)
- Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial. (2017) (0)
- Erratum: A nodal- and ALK4-independent signaling pathway activated by cripto-1 through glypican-1 and c-Src, (Cancer Research (March 15, 2003) (1192-1197)) (2003) (0)
- 422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018) (2022) (0)
- H03*Circulating-free tumor DNA as a surrogate for determination of EGFR status: the Italian experience within the ASSESS study (2015) (0)
- Faculty Opinions recommendation of Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. (2007) (0)
- Risk Management Activities in a Lung Cancer Multidisciplinary Team at a Comprehensive Cancer Center: Results of a Prospective Analysis (2022) (0)
- Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? (2005) (0)
- Faculty Opinions recommendation of Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. (2007) (0)
- Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol (2019) (0)
- Neutrophil/lymphocyte ratio as surrogate of cetuximab antibody-dependent cell-mediated cytotoxicity in first line metastatic colorectal cancer: A preliminary and exploratory analysis of the ERMES phase III trial. (2018) (0)
- Circulating free tumour-derived DNA (ctDNA) to detect EGFR mutation in patients (pts) with advanced NSCLC (aNSCLC): French subset analysis of the ASSESS study (2016) (0)
- Exploration of Targeted Anti-tumor Therapy: a contribution to the development of targeted therapies (2020) (0)
- PCN80 A Case Study in Molecular Diagnostic: A Comparison between an NGS-Based Approach Versus a Single-GENE Testing Approach in Ansclc and Mcrc Patients for an Italian Hospital (2020) (0)
- Subject Index Vol. 77, Suppl. 1, 2009 (2010) (0)
- Abstract 937: Molecular analysis of KRAS exon 2 wild type colorectal cancer patients enrolled in the CAPRI clinical trial reveals high degree of tumor heterogeneity (2014) (0)
- Monitoring response to therapy by testing circulating tumor DNA in urine (2017) (0)
- Circulating Tumor Cells and ctDNA in NSCLC (2019) (0)
- 1346P Diagnosis of early-stage cancers in carriers of BRCA1/2 pathogenetic variants: Two years of activity of the multidisciplinary team for hereditary cancers (2022) (0)
- Abstract 4891: Comprehensive genetic profiling of chromosomal translocations in lung cancer tumors: development and validation of a next-generation sequencing panel in an international multicenter study (2015) (0)
- Abstract 5694: Multi institutional evaluation of a new NGS assay for mutation detection from cfDNA in lung cancer (2017) (0)
- Techniques and New Diagnostic Technologies (Limitations, Applications) (2015) (0)
- 94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations (2021) (0)
- C linical P harmacology Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions (2006) (0)
- 934 Biological mechanisms in the different etiologies of Merkel cell carcinoma patients: polyomavirus or UV exposure (2021) (0)
- Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer-and lymphokine-activated-killer-mediated cytotoxicity (2005) (0)
- Signal Transduction Inhibitors in the Treatment of Breast Cancer (2009) (0)
- Results of the Second Pilot External Quality Assurance Scheme for Somatic Egfr Mutation Testing in Non-Small-Cell Lung Cancer (NSCLC) (2012) (0)
- Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study (2018) (0)
- P5-06-11: Quercetin-3-Methyl Ether Inhibits Lapatinib-Sensitive and Lapatinib-Resistant Breast Cancer Cell Growth by Inducing G2/M Arrest and Apoptosis. (2011) (0)
- Evaluation of cost-effectiveness of early KRAS testing in high-risk recurrence colorectal cancer patients in Italy. (2012) (0)
- A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants (2022) (0)
- Abstract 142: The EGFR signaling modulates in mesenchymal stem cells the expression of microRNAs involved in the interaction with breast cancer cells (2019) (0)
- 308 Transcriptomic analysis of melanoma patients in adjuvant setting treated with anti PD1 therapy: real life study (2021) (0)
- Abstract 2251: Intra-tumor heterogeneity in non-small-cell lung cancer (NSCLC) carrying EGFR mutations (2016) (0)
- 5-aza-2-deoxycytidine affects growth and surface cell phenotype of colon carcinoma CaCo-2 cells (1990) (0)
- Targeted sequencing of plasma‐derived cfDNA in patients with metastatic NSCLC: 57P (2018) (0)
- P3.01-068 Investigation of Low Plasma/Tissue EGFR Concordance in Russia: Follow-up to the IGNITE Global Diagnostic Study (2017) (0)
- Reviewer ' s report Title : Regulation of MCP-1 secretion in a novel bone-tumor coculture model Version : 1 Date : 10 September 2008 (0)
- Endocrine-Related Cancer ( 2000 ) 7 199 – 226 The EGF-CFC family : novel epidermal growth factor-related proteins in development and cancer (2001) (0)
- Faculty Opinions recommendation of Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. (2006) (0)
- Pneumocystis jirovecii Pneumonia in a Patient with Lung Adenocarcinoma and EGFR Mutation Treated with Afatinib During the Coronavirus Pandemic 2019 (2020) (0)
- Abstract 1509: Transcriptome analysis reveals significant effects of EGFR signaling on the secretome of mesenchymal stem cells. (2013) (0)
- The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic (2020) (0)
- EPHA2 Is aPredictiveBiomarkerofResistanceand a Potential Therapeutic Target for Improving AntiepidermalGrowthFactorReceptor Therapy in Colorectal Cancer (2019) (0)
- Interferon induces restoration of chemosensitivity in drug-resistant human colon carcinoma cell line (1990) (0)
- Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study. (2022) (0)
- Breast and Colon Carcinomas: Detection with Plasma CRIPTO-1 (2008) (0)
- Higher quality standards should be aimed for: feedback from EQA for KRAS mutation testing in colorectal cancer (2013) (0)
- The Clinical and Translational Research Activities at the INT – IRCCS “Fondazione Pascale” Center (Naples, Italy) during the COVID-19 Pandemic (2020) (0)
- Correction: Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor γ Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome (2011) (0)
- PUB071 Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC) (2017) (0)
- Abstract 4343: Effects of the co-expression of RANTES and IL-6 on the transformed phenotype of breast cancer cells (2017) (0)
- Health-related quality of life in recurrent platinum-sensitive ovarian cancer — results from the CALYPSO trial (0)
- Results of a global external quality assessment scheme for EGFR testing on liquid biopsy (2019) (0)
- Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium (2015) (0)
- The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences (2015) (0)
- 539PTUMOR HETEROGENEITY AND EFFICACY OF FIRST-LINE CETUXIMAB + FOLFIRI IN KRAS MUTANT METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) OF THE CAPRI GOIM TRIAL. (2014) (0)
- Lurbinectedin in small cell lung cancer (2022) (0)
- Faculty Opinions recommendation of K-ras mutations and benefit from cetuximab in advanced colorectal cancer. (2008) (0)
- Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial (2023) (0)
- RAS testing in metastatic colorectal cancer: advances in Europe (2018) (0)
- Current practice of genomic profiling of patients with advanced solid tumors in Italy: the RATIONAL study (2023) (0)
- The new mutational model in oncology. What changes in welfare, clinical practice, research, and regulatory procedures? (2019) (0)
- Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. (2020) (0)
- Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion (2022) (0)
- 35LBA Zoledronic acid affects the ability of mesenchymal stem cells to sustain breast cancer progression (2009) (0)
- Amphiregulin as an autocrine growth factor for cHaras-and c-erbB2-transformed human mammary epithelial cells ( Haras / c-neu / breast cancer ) (0)
- Phorbol-12-myristate-13-acetate (PMA) induces resistance of human melanoma cells to NK and LAK-mediated cytotoxicity. (1992) (0)
- Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts) (2016) (0)
- Endocrine therapy plus zoledronic acid in premenopausal breast cancer. (2009) (0)
- Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials. (2023) (0)
- D22PACER – A multicentre, single-arm, two-stage, phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer (mCRC) (2016) (0)
- Faculty Opinions recommendation of Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. (2012) (0)
- Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS. (2019) (0)
- Faculty Opinions recommendation of Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009) (0)
- Corrigendum to ‘COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)’ [ESMO Open Volume 6, Issue 3, June 2021, 100165] (2021) (0)
- Results of a worldwide external quality assessment of cfDNA testing in lung Cancer (2022) (0)
- Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. (2009) (0)
- ASBL report from the first European cfDNA consensus meeting (2019) (0)
- SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system (2021) (0)
- 540PAnalysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial (2017) (0)
- P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nicola Normanno?
Nicola Normanno is affiliated with the following schools:
